Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2022)

Treatment of renal cell carcinoma (RCC) has changed with expanding indications for robotic partial nephrectomy and inclusion of new Food and Drug Administration (FDA) approved treatments for advanced RCC. This course will focus on didactic case discussions using videotape analysis of surgical treatment, setup and successful completion of robotic partial nephrectomy, complication management and how to optimize outcomes. Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors, with an update on active clinical trials. There will be discussion focus on how to monitor, and algorithms for when to switch treatment.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

AstraZeneca
Bristol Myers Squibb
Merck & Co., Inc.
Pfizer, Inc.

Target Audience

  • Urologists
  • Residents

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma.
  2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma.
  3. Identify appropriate treatment options for management of complex cases.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/18/2022
Course expires: 
05/18/2023
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Benjamin Lee, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

A. Oliver Sartor, MD

has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Endocyte;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tenebio;.
has a financial relationship (Consultant or Advisor (Oncology)) with Isotopen Technologien Meunchen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clarity Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myriad;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Invitae;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Jannsen;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Constellation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Noxopharm;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bristol Myers Squibb;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theragnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Noria Therapeutics Inc.;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Denedron;.
has a financial relationship (Consultant or Advisor (General Urology)) with Jannsen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Progenics;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with EMD Serono;.
has a financial relationship (Consultant or Advisor (Oncology)) with POINT Biopharma;.
has a financial relationship (Consultant or Advisor (Oncology)) with Fusion;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myovant;.
has a financial relationship (Consultant or Advisor (General Urology)) with Constellation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bavarian Nordic;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Advancel Accelerator Applications (AAA);.

Chandru Sundaram, MD,FACS,FRCS

has a financial relationship (Independent contractor) with Endourological Society;.
has a financial relationship (Independent contractor) with Journal of Endourology;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.